Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Journal of Alzheimer's Disease

Volumn 48, Issue 2, 2015, Pages 403-410

  Matsunaga, Shinji ^a   Kishi, Taro ^a   Annas, Peter ^b   Basun, Hans ^b,c   Hampel, Harald ^d   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UPPSALA UNIVERSITY   (Sweden)

^c BioArctic Neuroscience   (Sweden)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer's disease; lithium; meta analysis; mild cognitive impairment; systematic review

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; LITHIUM; TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; LITHIUM DERIVATIVE; NOOTROPIC AGENT;

ADVERSE OUTCOME; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; DEATH; DRUG EFFICACY; HUMAN; MENTAL PERFORMANCE; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; DRUG EFFECTS; META ANALYSIS;

ALZHEIMER DISEASE; COGNITION; HUMANS; LITHIUM COMPOUNDS; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941278298     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150437     Document Type: Review

References (22)

1. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93, 8455-8459.
2. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6, 1664-1668.
3. Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41, 789-813.
4. Hong M, Chen DC, Klein PS, Lee VM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326-25332.
5. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, Anderton BH (1999) Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45, 995-1003.
6. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995.
7. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24, 739-749.
8. Kessing LV, Forman JL, Andersen PK (2010) Does lithium protect against dementia? Bipolar Disord 12, 87-94.
9. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: A randomized, singleblind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
10. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry 198, 351-356.
11. Nunes MA, Viel TA, Buck HS (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10, 104-107.
12. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
13. Molloy DW, Standish TI. (1997) A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 9(Suppl 1), 87-94; discussion 143-150.
14. Cohn LD, Becker BJ (2003) How meta-analysis increases statistical power. Psychol Methods 8, 243-253.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7, 177-188.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. BMJ339, b2535.
17. Cohen J (1988) Statistical Power Analysis in the Behavioral Sciences. Erlbaum, Hillsdale, NJ.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ327, 557-560.
19. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M (2013) A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis 35, 349-361.
20. Aprahamian I, Santos FS, dos Santos B, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV (2014) Long-term, low-dose lithium treatment does not impair renal function in the elderly: A 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry 75, e672-e678.
21. Boada M, Arranz FJ (2013) Transdermal is better than oral: Observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord 35, 23-33.
22. Li X, Zhang ZJ (2015) Neuropsychological and neuroimaging characteristics of amnestic mild cognitive impairment subtypes: A selective overview. CNS Neurosci Ther. doi: 10.1111/cns.12391